

# Anders SÅnnerborg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1882265/publications.pdf>

Version: 2024-02-01

346  
papers

14,947  
citations

23500

58  
h-index

29081

104  
g-index

350  
all docs

350  
docs citations

350  
times ranked

16890  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling. <i>IScience</i> , 2022, 25, 103607.	1.9	7
2	Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1103-1116.	1.8	4
3	Peripheral blood CD4+CCR6+ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals. <i>Communications Biology</i> , 2022, 5, 357.	2.0	2
4	Characterization of the Upper Respiratory Bacterial Microbiome in Critically Ill COVID-19 Patients. <i>Biomedicine</i> , 2022, 10, 982.	1.4	8
5	Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection. <i>Life Science Alliance</i> , 2022, 5, e202201405.	1.3	7
6	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. <i>Pathogens</i> , 2022, 11, 546.	1.2	3
7	Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5534.	1.8	10
8	T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin. <i>PLoS Pathogens</i> , 2022, 18, e1010555.	2.1	5
9	Contagiousness in treated HIV-1 infection. <i>Infectious Diseases</i> , 2021, 53, 1-8.	1.4	8
10	Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine. <i>ACS Infectious Diseases</i> , 2021, 7, 1104-1115.	1.8	19
11	Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. <i>HIV Medicine</i> , 2021, 22, 22-27.	1.0	10
12	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3799-3809.	1.9	24
13	HIV-1 CRF07_BC transmission dynamics in China: two decades of national molecular surveillance. <i>Emerging Microbes and Infections</i> , 2021, 10, 1919-1930.	3.0	15
14	High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden. <i>Aids</i> , 2021, 35, 227-234.	1.0	3
15	Distinct lipid profile, low-level inflammation, and increased antioxidant defense signature in HIV-1 elite control status. <i>IScience</i> , 2021, 24, 102111.	1.9	14
16	Cytotoxic Lymphocytes Target HIV-1 Gag Through Granzyme M-Mediated Cleavage. <i>Frontiers in Immunology</i> , 2021, 12, 669347.	2.2	2
17	Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 339-350.	2.4	31
18	Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death. <i>Heliyon</i> , 2021, 7, e07134.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Whole-Genome Metagenomic Analysis of the Gut Microbiome in HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2021, 12, 667718.	1.5	15
20	Post-migration acquisition of HIV: Estimates from four European countries, 2007 to 2016. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
21	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€“Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
22	Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100159.	2.5	65
23	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020, 183, 158-168.e14.	13.5	1,561
24	Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses. <i>Journal of Proteome Research</i> , 2020, 19, 4259-4274.	1.8	32
25	Delayed Treatment for People Living with HIV in China, 2004â€“2016: An Analysis of An Observational Cohort. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1809.	1.2	16
26	Antiretroviral treatment for HIV infection: Swedish recommendations 2019. <i>Infectious Diseases</i> , 2020, 52, 295-329.	1.4	13
27	Chromatin maturation of the HIV-1 provirus in primary resting CD4+Â T cells. <i>PLoS Pathogens</i> , 2020, 16, e1008264.	2.1	19
28	HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. <i>Viruses</i> , 2020, 12, 475.	1.5	20
29	HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2662-2668.	1.1	9
30	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
31	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
32	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
33	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
34	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
35	GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. <i>Frontiers in Microbiology</i> , 2019, 10, 1227.	1.5	43
36	A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 569.	1.3	6

#	ARTICLE	IF	CITATIONS
37	A5â€fNear full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden. <i>Virus Evolution</i> , 2019, 5, .	2.2	0
38	MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. <i>Viruses</i> , 2019, 11, 806.	1.5	3
39	Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium. <i>Frontiers in Microbiology</i> , 2019, 10, 613.	1.5	21
40	Microfluidic centrifugation assisted precipitation based DNA quantification. <i>Lab on A Chip</i> , 2019, 19, 1657-1664.	3.1	11
41	Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics. <i>Journal of Infection</i> , 2019, 78, 402-408.	1.7	4
42	Strain-specific effect on biphasic DNA binding by HIV-1 integrase. <i>Aids</i> , 2019, 33, 588-592.	1.0	6
43	HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
44	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. <i>Aids</i> , 2019, 33, 315-326.	1.0	4
45	HIV elite control is associated with reduced TRAILshort expression. <i>Aids</i> , 2019, 33, 1757-1763.	1.0	5
46	Optimal probability weights for estimating causal effects of timeâ€varying treatments with marginal structural Cox models. <i>Statistics in Medicine</i> , 2019, 38, 1891-1902.	0.8	6
47	Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. <i>Eurosurveillance</i> , 2019, 24, .	3.9	4
48	Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 733-738.	1.1	20
49	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	2.9	105
50	Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. <i>Aids</i> , 2018, 32, 877-884.	1.0	9
51	Prophylaxis and treatment of HIV-1 infection in pregnancy â€“ Swedish Recommendations 2017. <i>Infectious Diseases</i> , 2018, 50, 495-506.	1.4	14
52	Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers. <i>EBioMedicine</i> , 2018, 27, 40-50.	2.7	28
53	Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. <i>Aids</i> , 2018, 32, 469-476.	1.0	31
54	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018, 32, 161-169.	1.0	19

#	ARTICLE	IF	CITATIONS
55	Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution. <i>Frontiers in Microbiology</i> , 2018, 9, 2358.	1.5	20
56	Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. <i>PLoS ONE</i> , 2018, 13, e0200505.	1.1	21
57	Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. <i>Aids</i> , 2018, 32, 1475-1484.	1.0	8
58	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. <i>PLoS Pathogens</i> , 2018, 14, e1006973.	2.1	30
59	Antiretroviral potency of 4'-ethynyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2721-2728.	1.3	12
60	Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 19.	2.2	20
61	Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes. <i>Frontiers in Microbiology</i> , 2018, 9, 1754.	1.5	19
62	Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. <i>Scientific Reports</i> , 2018, 8, 7556.	1.6	28
63	Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods. <i>Current HIV Research</i> , 2018, 16, 113-120.	0.2	0
64	Increased replication capacity following evolution of PYX insertion in Gag p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa. <i>Journal of Medical Virology</i> , 2017, 89, 106-111.	2.5	12
65	Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. <i>Scientific Reports</i> , 2017, 7, 40354.	1.6	65
66	Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1680-1687.	1.1	2
67	A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 decline trajectory model. <i>HIV Medicine</i> , 2017, 18, 677-684.	1.0	23
68	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	2.9	46
69	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	1.9	20
70	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. <i>Scientific Reports</i> , 2017, 7, 666.	1.6	12
71	Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers. <i>Scientific Reports</i> , 2017, 7, 6269.	1.6	79
72	Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden. <i>Scientific Reports</i> , 2017, 7, 6371.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses—“an analysis of a prospective country-wide cohort. BMC Infectious Diseases, 2017, 17, 37.	1.3	11
74	Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infectious Diseases, 2017, 49, 1-34.	1.4	24
75	Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. HIV Medicine, 2017, 18, 305-307.	1.0	108
76	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
77	PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context. Bioinformatics, 2017, 33, 3993-3995.	1.8	16
78	A21—HIV-1 sub-subtype F1 outbreak among MSM in Belgium. Virus Evolution, 2017, 3, .	2.2	6
79	Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. PLoS ONE, 2017, 12, e0180140.	1.1	3
80	Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort. PLoS ONE, 2017, 12, e0182384.	1.1	4
81	Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS ONE, 2017, 12, e0178942.	1.1	11
82	Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance. Eurosurveillance, 2017, 22, .	3.9	6
83	Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden. HIV Medicine, 2016, 17, 425-435.	1.0	40
84	Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden. International Journal of Cancer, 2016, 139, 1471-1479.	2.3	11
85	Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. BMC Infectious Diseases, 2016, 16, 305.	1.3	50
86	Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster. AIDS Research and Human Retroviruses, 2016, 32, 471-474.	0.5	18
87	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
88	Multiplexed next-generation sequencing and de novo assembly to obtain near full-length HIV-1 genome from plasma virus. Journal of Virological Methods, 2016, 236, 98-104.	1.0	19
89	Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam. BMC Infectious Diseases, 2016, 16, 759.	1.3	12
90	The global spread of HIV-1 subtype B epidemic. Infection, Genetics and Evolution, 2016, 46, 169-179.	1.0	60

#	ARTICLE	IF	CITATIONS
91	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. <i>Virus Evolution</i> , 2016, 2, vew010.	2.2	68
92	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	4.6	217
93	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016, 5, 135-146.	2.7	328
94	Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 367-371.	1.3	6
95	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	2.9	135
96	Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. <i>Lancet HIV</i> , the, 2016, 3, e166-e174.	2.1	43
97	Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 80-84.	0.5	15
98	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Infectious Diseases</i> , 2016, 48, 93-98.	1.4	7
99	Symptomatic Patients without Epidemiological Indicators of HIV Have a High Risk of Missed Diagnosis: A Multi-Centre Cross Sectional Study. <i>PLoS ONE</i> , 2016, 11, e0162503.	1.1	8
100	Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection. <i>Clinical Immunology</i> , 2015, 161, 180-189.	1.4	9
101	Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 329-337.	0.9	65
102	Gut microbiota diversity predicts immune status in HIV-1 infection. <i>Aids</i> , 2015, 29, 2409-2418.	1.0	238
103	Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. <i>PLoS ONE</i> , 2015, 10, e0137635.	1.1	14
104	Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005072.	2.1	204
105	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015, 16, 297-306.	1.0	9
106	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1735-1744.	1.9	62
107	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts <math>\leq 200 \text{ Cells}/\mu\text{L}</math>: TB-HAART Study, a Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0122587.	1.1	23
108	Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades. <i>PLoS ONE</i> , 2014, 9, e99390.	1.1	48



#	ARTICLE	IF	CITATIONS
109	Minority Drug-Resistant HIV-1 Variants in Treatment Naïve East-African and Caucasian Patients Detected by Allele-Specific Real-Time PCR. PLoS ONE, 2014, 9, e111042.	1.1	10
110	Time on drug analysis based on real life data. Journal of the International AIDS Society, 2014, 17, 19790.	1.2	0
111	Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors. Viruses, 2014, 6, 3535-3562.	1.5	27
112	T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. PLoS Pathogens, 2014, 10, e1004251.	2.1	273
113	Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scandinavian Journal of Infectious Diseases, 2014, 46, 673-677.	1.5	24
114	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013. Scandinavian Journal of Infectious Diseases, 2014, 46, 401-411.	1.5	5
115	High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. Scandinavian Journal of Infectious Diseases, 2014, 46, 624-632.	1.5	6
116	Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. Aids, 2014, 28, 2319-2322.	1.0	19
117	Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or "blips" in HIV-1 subtype C. Aids, 2014, 28, 2635-2636.	1.0	3
118	Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. Journal of Hepatology, 2014, 61, 957-961.	1.8	30
119	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infectious Diseases, 2014, 14, 407.	1.3	43
120	Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. Journal of Antimicrobial Chemotherapy, 2014, 69, 3349-3355.	1.3	28
121	P770 LOWER UPTAKE OF HCV TREATMENT THAN HIV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS. Journal of Hepatology, 2014, 60, S327.	1.8	0
122	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. PLoS ONE, 2014, 9, e94495.	1.1	32
123	Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity. PLoS ONE, 2014, 9, e101508.	1.1	3
124	Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden. Journal of the International AIDS Society, 2014, 17, 18841.	1.2	13
125	Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology, 2013, 10, 36.	0.9	52
126	HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology, 2013, 10, 7.	0.9	129



#	ARTICLE	IF	CITATIONS
127	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. <i>Infection, Genetics and Evolution</i> , 2013, 19, 349-360.	1.0	4
128	Evolution of fibrosis during <sc>HCV</sc> recurrence after liver transplantation â€“ influence of <sc>IL</sc>28B <sc>SNP</sc> and response to pegâ€“<sc>IFN</sc> and ribavirin treatment. <i>Journal of Viral Hepatitis</i> , 2013, 20, 770-778.	1.0	12
129	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. <i>Infection, Genetics and Evolution</i> , 2013, 18, 125-131.	1.0	58
130	Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients with HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 564-573.	0.5	9
131	497 SPONTANEOUS CLEARANCE OR CHRONIC EVOLUTION OF HCV IN HIV/HCV CO-INFECTED PATIENTS â€“ INFLUENCE OF THE IL28B GENOTYPE. <i>Journal of Hepatology</i> , 2013, 58, S204.	1.8	2
132	<sc>HCV RNA</sc> decline in chronic <sc>HCV</sc> genotype 2 and 3 during standard of care treatment according to <sc>IL</sc>28B polymorphism. <i>Journal of Viral Hepatitis</i> , 2013, 20, 193-199.	1.0	16
133	Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 543-551.	1.5	14
134	Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. <i>Journal of Infectious Diseases</i> , 2013, 207, S101-S106.	1.9	21
135	AIDS and HIV Infection after Thirty Years. <i>AIDS Research and Treatment</i> , 2013, 2013, 1-3.	0.3	1
136	Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe. <i>Journal of Infectious Diseases</i> , 2013, 207, 1216-1220.	1.9	53
137	HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1053-1056.	1.4	39
138	Evaluation of etravirine resistance in clinical samples by a simple phenotypic Test. <i>Journal of Medical Virology</i> , 2013, 85, 703-708.	2.5	7
139	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. <i>Blood</i> , 2013, 121, 1124-1135.	0.6	347
140	Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. <i>BMC Infectious Diseases</i> , 2013, 13, 537.	1.3	8
141	Human APOBEC3Gâ€“mediated hypermutation is associated with antiretroviral therapy failure in HIVâ€“1 subtype Câ€“infected individuals. <i>Journal of the International AIDS Society</i> , 2013, 16, 18472.	1.2	25
142	Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e55038.	1.1	30
143	Long-Term Efficacy of First Line Antiretroviral Therapy in Indian HIV-1 Infected Patients: A Longitudinal Cohort Study. <i>PLoS ONE</i> , 2013, 8, e55421.	1.1	22
144	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. <i>PLoS ONE</i> , 2013, 8, e61436.	1.1	17

#	ARTICLE	IF	CITATIONS
145	Molecular Dating of HIV-1 Subtype C from Bangladesh. PLoS ONE, 2013, 8, e79193.	1.1	8
146	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.1	145
147	Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997â€“2011. PLoS ONE, 2013, 8, e59337.	1.1	21
148	HIV Care in the Swedish-Danish HIV Cohort 1995-2010, Closing the Gaps. PLoS ONE, 2013, 8, e72257.	1.1	42
149	Monitoring the efficacy of antiretroviral therapy by a simple reverse transcriptase assay in HIV-infected adults in rural Vietnam. Future Virology, 2012, 7, 923-931.	0.9	8
150	Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort. Intervirology, 2012, 55, 160-166.	1.2	8
151	Higher Prevalence of Predicted X4-Tropic Strains in Perinatally Infected Older Children With HIV-1 Subtype C in India. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 347-353.	0.9	15
152	Optimizing background therapy in treatment-experienced HIV-1 patients by rules-based algorithms and bioinformatics. Future Virology, 2012, 7, 749-757.	0.9	2
153	Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. Scandinavian Journal of Infectious Diseases, 2012, 44, 201-208.	1.5	34
154	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naïve HIV-1 infected patients. Retrovirology, 2012, 9, 81.	0.9	23
155	Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project. Intervirology, 2012, 55, 123-127.	1.2	43
156	Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: A cross-sectional cohort study. Scandinavian Journal of Infectious Diseases, 2012, 44, 108-114.	1.5	9
157	Emergence of unique recombinant forms (URFs) in Indian HIV-1 epidemic: data from nationwide clinical cohort between 2007 and 2011. Retrovirology, 2012, 9, .	0.9	1
158	Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam. Infection, Genetics and Evolution, 2012, 12, 448-452.	1.0	19
159	Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003â€“2010. PLoS ONE, 2012, 7, e33484.	1.1	56
160	Molecular Epidemiology of HIV-1 Subtypes in India: Origin and Evolutionary History of the Predominant Subtype C. PLoS ONE, 2012, 7, e39819.	1.1	64
161	Characterization of HIV-Specific CD4+ T Cell Responses against Peptides Selected with Broad Population and Pathogen Coverage. PLoS ONE, 2012, 7, e39874.	1.1	22
162	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010. Scandinavian Journal of Infectious Diseases, 2011, 43, 411-423.	1.5	10

#	ARTICLE	IF	CITATIONS
163	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , 2011, 11, 394-407.	4.6	218
164	High Mobility Group Box Protein-1 in HIV-1 Infection: Connecting Microbial Translocation, Cell Death and Immune Activation. <i>Current HIV Research</i> , 2011, 9, 6-10.	0.2	23
165	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	1.0	378
166	Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). <i>HIV Medicine</i> , 2011, 12, 211-218.	1.0	32
167	Overcoming obstacles to late presentation for HIV infection in Europe. <i>HIV Medicine</i> , 2011, 12, 246-249.	1.0	10
168	Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy. <i>AAPS Journal</i> , 2011, 13, 598-605.	2.2	14
169	Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. <i>AIDS Research and Therapy</i> , 2011, 8, 21.	0.7	10
170	HIV-1 mutational pathways under multidrug therapy. <i>AIDS Research and Therapy</i> , 2011, 8, 26.	0.7	12
171	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	1.3	56
172	Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. <i>Aids</i> , 2010, 24, 1733-1737.	1.0	60
173	The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 349-357.	0.8	22
174	A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden. <i>Journal of the International AIDS Society</i> , 2010, 13, P169.	1.2	4
175	Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients. <i>Journal of the International AIDS Society</i> , 2010, 13, P31-P31.	1.2	1
176	Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction. <i>PLoS ONE</i> , 2010, 5, e9044.	1.1	2
177	Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models. <i>PLoS ONE</i> , 2010, 5, e13753.	1.1	21
178	Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro. <i>Journal of General Virology</i> , 2010, 91, 1800-1809.	1.3	28
179	Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1 Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 533-540.	0.5	14
180	Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno—THEO on a Large Clinical Database. <i>Journal of Infectious Diseases</i> , 2009, 199, 999-1006.	1.9	40

#	ARTICLE	IF	CITATIONS
181	Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe. <i>Journal of Infectious Diseases</i> , 2009, 200, 1503-1508.	1.9	213
182	Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. <i>European Journal of Immunology</i> , 2009, 39, 902-911.	1.6	91
183	Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. <i>Journal of Medical Virology</i> , 2009, 81, 1-8.	2.5	4
184	Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. <i>AIDS Research and Therapy</i> , 2009, 6, 15.	0.7	29
185	Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. <i>HIV Medicine</i> , 2009, 10, 94-102.	1.0	32
186	Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. <i>HIV Medicine</i> , 2009, 10, 111-115.	1.0	7
187	Treatment of HIV infection: Swedish recommendations 2009. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 788-807.	1.5	16
188	CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4 $\beta$ -hydroxycholesterol levels. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 775-781.	0.8	54
189	Treatment of chronic hepatitis B infection: An update of Swedish recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 436-450.	1.5	10
190	Selecting anti-HIV therapies based on a variety of genomic and clinical factors. <i>Bioinformatics</i> , 2008, 24, i399-i406.	1.8	50
191	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 451-461.	1.5	8
192	Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy. <i>PLoS ONE</i> , 2008, 3, e3470.	1.1	45
193	Antiretroviral treatment of HIV infection: Swedish recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 486-507.	1.5	18
194	Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 417-422.	0.9	74
195	Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. <i>Aids</i> , 2007, 21, 869-871.	1.0	30
196	Authors' Response to "Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapy". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 118-119.	0.9	0
197	Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. <i>Aids</i> , 2007, 21, 565-574.	1.0	63
198	A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment. <i>Patient Education and Counseling</i> , 2007, 67, 108-116.	1.0	13

#	ARTICLE	IF	CITATIONS
199	Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure. <i>HIV Medicine</i> , 2007, 8, 504-510.	1.0	5
200	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 86-103.	1.5	7
201	Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 371-374.	1.5	9
202	HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. <i>Cytokine</i> , 2006, 34, 17-23.	1.4	36
203	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 191-198.	0.7	145
204	Adherence to treatment in Swedish HIV-infected patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 605-616.	0.7	45
205	Differences in adherence and motivation to HIV therapy—two independent assessments in 1998 and 2002. <i>International Journal of Clinical Pharmacy</i> , 2006, 28, 248-256.	1.4	18
206	Assessing and achieving readiness to initiate HIV medication. <i>Patient Education and Counseling</i> , 2006, 62, 21-30.	1.0	35
207	Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. <i>Journal of Virological Methods</i> , 2005, 127, 100-107.	1.0	13
208	Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir. <i>Journal of Medical Virology</i> , 2005, 76, 447-451.	2.5	5
209	Impact of Therapeutic Immunization on HIV-1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 607-617.	1.9	111
210	Expansion of CD7low and CD7negative CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. <i>Blood</i> , 2004, 104, 3672-3678.	0.6	32
211	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. <i>Antiviral Therapy</i> , 2004, 9, 829-848.	0.6	114
212	Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. <i>Virology</i> , 2003, 314, 179-189.	1.1	40
213	Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research. <i>Journal of Medical Virology</i> , 2003, 69, 195-201.	2.5	13
214	Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function. <i>European Journal of Pain</i> , 2003, 7, 23-31.	1.4	55
215	Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 13-19.	0.5	13
216	Antiretroviral Treatment of Human Immunodeficiency Virus Infection: Swedish Recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 155-167.	1.5	15

#	ARTICLE	IF	CITATIONS
217	Use of genotypic assays for the detection of antiretroviral resistance: a legal proceeding, Rome, 22â€“23 april 2002. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 5-5.	1.5	0
218	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. <i>Aids</i> , 2002, 16, 1039-1044.	1.0	99
219	Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. <i>Aids</i> , 2002, 16, 683-692.	1.0	127
220	Low Levels of Perforin Expression in CD8+T Lymphocyte Granules in Lymphoid Tissue during Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 1355-1358.	1.9	56
221	Quantification of Human Immunodeficiency Virus Type 1 Proviral DNA by the TaqMan Real-Time PCR Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3883-3884.	1.8	36
222	Monophyletic HIV Type 1 CRF02-AG in a Nosocomial Outbreak in Benghazi, Libya. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 727-732.	0.5	31
223	Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. <i>Journal of Medical Virology</i> , 2002, 68, 473-478.	2.5	12
224	Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. <i>Clinical and Experimental Immunology</i> , 2002, 127, 486-494.	1.1	47
225	Initiation of Therapy during Primary HIV Type 1 Infection Results in a Continuous Decay of Proviral DNA and a Highly Restricted Viral Evolution. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 409-416.	0.5	25
226	Broad Spectrum of Time of Detection, Primary Symptoms and Disease Progression in Infants with HIV-1 Infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001, 20, 0159-0166.	1.3	4
227	Quantitative single cell methods that identify cytokine and chemokine expression in dendritic cells. <i>Journal of Immunological Methods</i> , 2001, 249, 207-222.	0.6	12
228	Recent Origin of Human Immunodeficiency Virus Type 1 Variants in Resting CD4+T Lymphocytes in Untreated and Suboptimally Treated Subjects. <i>Journal of Infectious Diseases</i> , 2001, 184, 1392-1401.	1.9	16
229	Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. <i>Aids</i> , 2001, 15, 1359-1368.	1.0	25
230	Smaller Amounts of Antiretroviral Drugs Are Needed When Combined with an Active Ribozyme against HIV-1. <i>Molecular Therapy</i> , 2001, 3, 531-535.	3.7	5
231	Switching Antiretroviral Therapy From an Enzyme-Inducing Drug. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 637-638.	1.0	0
232	Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. <i>Aids</i> , 2000, 14, 2333-2339.	1.0	116
233	Rapid and Simple Determination of Indinavir in Serum, Urine, and Cerebrospinal Fluid Using High-Performance Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 626-629.	1.0	12
234	The Quest Trial, a paradigm of HIV collaborative research. <i>Nature Medicine</i> , 2000, 6, 1194-1194.	15.2	11



#	ARTICLE	IF	CITATIONS
235	Antiretroviral therapy may improve sensory function in HIV-infected patients. <i>Neurology</i> , 2000, 54, 2120-2127.	1.5	66
236	Viral dynamics in primary HIV-1 infection. <i>Aids</i> , 2000, 14, 2283-2291.	1.0	92
237	Variability and Immunogenicity of Human Immunodeficiency Virus Type 1 p24 Gene Quasispecies. <i>Vaccine Journal</i> , 2000, 7, 377-383.	2.6	7
238	High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1379-1384.	0.5	18
239	HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation. <i>Aids</i> , 1999, 13, 2013-2021.	1.0	29
240	HIV viral load and response to antileishmanial chemotherapy in co-infected patients. <i>Aids</i> , 1999, 13, 1921-1925.	1.0	66
241	Longitudinal Quantification of Human Immunodeficiency Virus Type 1 DNA and RNA in Long-Term Nonprogressors. <i>Journal of Infectious Diseases</i> , 1999, 179, 1542-1548.	1.9	25
242	Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. <i>Gut</i> , 1999, 44, 274-278.	6.1	12
243	Long-Term Pattern of HIV-1 RNA Load in Perinatally Infected Children. <i>Scandinavian Journal of Infectious Diseases</i> , 1999, 31, 337-343.	1.5	12
244	No Association of HIV Type 1 Long Terminal Repeat Sequence Pattern with Long-Term Nonprogression and in Vivo Viral Replication Levels in European Subjects. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 609-617.	0.5	8
245	Phenotypic Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Isolates of Ethiopian AIDS Patients. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 647-653.	0.5	133
246	Similar HIV-1 Subtype A V3 Loop Sequences Are Found in Dual HIV-1/HIV-2 and HIV-1-Only Seropositives in Ghana. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 775-779.	0.5	3
247	DNA Sequence of the Long Terminal Repeat of Human Immunodeficiency Virus Type 1 Subtype A through G. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 485-488.	0.5	25
248	Long-Term Effects of Antiretroviral Combination Therapy on HIV Type 1 DNA Levels. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1249-1254.	0.5	17
249	Pain in ambulatory HIV-infected patients with and without intravenous drug use. <i>European Journal of Pain</i> , 1999, 3, 157-164.	1.4	29
250	Long Terminal Repeat Promoter/Enhancer Activity of Different Subtypes of HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1293-1303.	0.5	85
251	Limited humoral immunity in hepatitis C virus infection. <i>Gastroenterology</i> , 1999, 116, 135-143.	0.6	147
252	Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. <i>Aids</i> , 1999, 13, 1295-1303.	1.0	99



#	ARTICLE	IF	CITATIONS
253	The Anti-HBs Response After 2 Different Accelerated Intradermal and Intramuscular Schemes for Hepatitis B Vaccination. <i>Scandinavian Journal of Infectious Diseases</i> , 1999, 31, 93-95.	1.5	13
254	Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. <i>Aids</i> , 1999, 13, 1227-1232.	1.0	64
255	Kinetics of $\hat{I}^2$ -Chemokine Levels during Anti-HIV Therapy. <i>Antiviral Therapy</i> , 1999, 4, 109-115.	0.6	6
256	Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998, 22, 499-501.	1.3	7
257	Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells. <i>Journal of Immunological Methods</i> , 1998, 214, 97-111.	0.6	55
258	Human and murine antibody recognition is focused on the ATPase/Helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein. <i>Hepatology</i> , 1998, 28, 219-224.	3.6	17
259	Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. , 1998, 56, 33-38.		32
260	Distribution of the CCR5 gene 32 base pair deletion and SDF1-3'A variant in healthy individuals from different populations. <i>Immunogenetics</i> , 1998, 48, 417-419.	1.2	40
261	Randomised, double-blind, placebo-controlled trial of interferon $\hat{I}\pm$ -2b with and without ribavirin for chronic hepatitis C. <i>Lancet, The</i> , 1998, 351, 83-87.	6.3	623
262	Nonsynonymous Mutations within the Human Immunodeficiency Virus Type 1 p17 Gene Are Clustered to Sequences Binding to the Host Human Leukocyte Antigen Class I Molecules. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 241-248.	0.5	25
263	<b>Sequence Note</b>: Full-Length Sequence of Human Immunodeficiency Virus Type 1 Subtype A, Recombined with Subtype C in the<i>env</i>V3 Domain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 289-292.	0.5	9
264	Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity. <i>Aids</i> , 1998, 12, 1973-1981.	1.0	6
265	Comparison of 3 Quantitative HCV RNA Assays - Accuracy of Baseline Viral Load to Predict Treatment Outcome in Chronic Hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 1998, 30, 441-446.	1.5	45
266	Pronounced Anti-HIV-1 Activity of Foscarnet in Patients Without Cytomegalovirus Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 51-53.	0.3	13
267	Cerebrospinal Fluid Mononuclear Cell Counts Influence CSF HIV-1 RNA Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 17, 214-219.	0.3	49
268	Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. <i>Aids</i> , 1998, 12, 2369-2375.	1.0	53
269	Characterization of the viral population during primary HIV-1 infection. <i>Aids</i> , 1998, 12, 839-847.	1.0	50
270	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. <i>Aids</i> , 1998, 12, 2007-2015.	1.0	77

#	ARTICLE	IF	CITATIONS
271	Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. <i>Aids</i> , 1998, 12, F203-F209.	1.0	82
272	Combination Treatment for Hepatitis C Can be Hazardous in Patients Co-Infected with HIV. <i>Antiviral Therapy</i> , 1998, 3, 233-234.	0.6	2
273	Dynamics of the HIV-1 Subtype Distribution in the Swedish HIV-1 Epidemic during the Period 1980 to 1993. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 343-345.	0.5	37
274	Genetic Evidence for Mother-to-Infant Transmission of Hepatitis G Virus. <i>Journal of Infectious Diseases</i> , 1997, 176, 281-285.	1.9	71
275	Variation of Hepatitis C Virus Hypervariable Region 1 in Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 1997, 175, 938-943.	1.9	45
276	Subtype-specific problems with quantification of plasma HIV-1 RNA. <i>Aids</i> , 1997, 11, 859-865.	1.0	146
277	Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions. <i>Research in Virology</i> , 1997, 148, 233-237.	0.7	3
278	Indinavir in cerebrospinal fluid of HIV-1-infected patients. <i>Lancet, The</i> , 1997, 350, 1823.	6.3	39
279	Cerebrospinal fluid analyses in HIV patients: a longitudinal study through six years. <i>European Journal of Neurology</i> , 1997, 4, 576-585.	1.7	1
280	Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR. <i>Journal of Virological Methods</i> , 1997, 69, 171-180.	1.0	17
281	Nosocomial transmission of hepatitis C virus. <i>Infection</i> , 1997, 25, 74-77.	2.3	54
282	HIV-1 subtype C epidemic in Ethiopia. <i>Aids</i> , 1997, 11, 1897.	1.0	5
283	DYNAMIC ANALYSIS OF HEPATITIS C VIRUS POLYMORPHISM IN PATIENTS WITH ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1997, 64, 170-172.	0.5	17
284	Prevalence and Risk Factors for HTLV-II Infection in 913 Injecting Drug Users in Stockholm, 1994. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 15, 381-386.	0.3	24
285	Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function. <i>Vaccine Journal</i> , 1997, 4, 104-106.	2.6	5
286	A Novel Ribozyme Target Site Located in the HIV-1 Nef Open Reading Frame. <i>Virology</i> , 1996, 219, 161-169.	1.1	29
287	Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 457-461.	0.8	91
288	Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. , 1996, 49, 155-160.		46

#	ARTICLE	IF	CITATIONS
289	Site-directed serology of HIV-1 subtype B infection: relation between virus specific antibody levels and disease progression. <i>Clinical and Experimental Immunology</i> , 1996, 106, 35-39.	1.1	5
290	Restriction of Hepatitis C Virus Heterogeneity during Prolonged Interferon- $\alpha$ Therapy in Relation to Changes in Virus Load. <i>Journal of Infectious Diseases</i> , 1996, 173, 992-996.	1.9	18
291	Full-Length Sequence of an Ethiopian Human Immunodeficiency Virus Type 1 (HIV-1) Isolate of Genetic Subtype C. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1329-1339.	0.5	86
292	Evaluation of a multiple peptide assay for typing of antibodies to the hepatitis C virus: Relation to genomic typing by the polymerase chain reaction. <i>Journal of Medical Virology</i> , 1995, 45, 50-55.	2.5	20
293	Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. <i>Journal of Medical Virology</i> , 1995, 45, 223-226.	2.5	49
294	Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. <i>Journal of Medical Virology</i> , 1995, 46, 43-47.	2.5	98
295	Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. <i>Hepatology</i> , 1995, 21, 918-922.	3.6	95
296	Transmission of Hepatitis C Virus by Transfusion in Å–rebro County, Sweden, 1990–1992. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 449-452.	1.5	21
297	Multiple Enhancer Motifs in HIV Type 1 Strains from Ethiopia. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 761-764.	0.5	28
298	Distinguishing Acute from Symptomatic Chronic Hepatitis C Virus (HCV) Infection by Site-Directed Serology of the HCV Structural Proteins. <i>Journal of Infectious Diseases</i> , 1995, 171, 1356-1359.	1.9	17
299	Human Immunodeficiency Virus Type 1-Infected Patients with No Disease Progression Display Highavidity Antibody Production to Autologous V3 Sequences. <i>Journal of Infectious Diseases</i> , 1995, 171, 509-509.	1.9	22
300	Efficacy of Human Leucocyte Alpha-Interferon Treatment for Chronic Hepatitis C Virus Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 319-324.	1.5	13
301	Prevention of nosocomial transmission of hepatitis C virus. <i>Lancet, The</i> , 1995, 346, 190.	6.3	9
302	Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein. <i>Journal of Clinical Microbiology</i> , 1995, 33, 778-780.	1.8	17
303	Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1870-1874.	1.8	27
304	Variability of the E2/NS1 Region of Swedish Hepatitis C Virus Strains and Its Correlation to Genotypes. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 255-261.	1.5	1
305	Evidence of No Change in V3 Loop Antibody Recognition Pattern in HIV Type 1-Infected Ethiopians between 1988 and 1993. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1551-1556.	0.5	19
306	Hepatitis C Virus Replication in Liver and Peripheral Blood Mononuclear Cells of Interferon- $\alpha$ -Treated and Untreated Patients with Chronic Hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 82-86.	0.6	22

#	ARTICLE	IF	CITATIONS
307	Parvovirus B19 infection in HIV-1 infected patients with anemia. <i>Infection</i> , 1994, 22, 356-358.	2.3	28
308	Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. <i>Journal of Virological Methods</i> , 1994, 47, 1-13.	1.0	33
309	A Cell-Binding Arg-Gly-Asp Sequence Is Present in Close Proximity to the Major Linear Antigenic Region of HCV NS3. <i>Biochemical and Biophysical Research Communications</i> , 1994, 202, 1352-1356.	1.0	9
310	Rapid Grouping of HIV-1 Infection in Subtypes A to E by V3 Peptide Serotyping and Its Relation to Sequence Analysis. <i>Biochemical and Biophysical Research Communications</i> , 1994, 205, 1658-1664.	1.0	41
311	Serum Hepatitis C Virus RNA Levels in Chronic Hepatitis C-Importance for outcome of interferon alfa-2b treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 263-270.	1.5	35
312	Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. <i>Vaccine Journal</i> , 1994, 1, 290-294.	2.6	20
313	Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in swedish blood donors. <i>Journal of Medical Virology</i> , 1993, 39, 57-61.	2.5	69
314	Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. <i>Journal of Medical Virology</i> , 1993, 39, 325-332.	2.5	36
315	Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. <i>Journal of Medical Virology</i> , 1993, 41, 99-102.	2.5	87
316	The neurotoxin-like sequence of human immunodeficiency virus GP120: A comparison of sequence data from patients with and without neurological symptoms. <i>Virus Genes</i> , 1993, 7, 23-31.	0.7	8
317	Sequence analysis of selected regions of the env (V3 loop and gp 41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains. <i>Archives of Virology</i> , 1993, 128, 229-239.	0.9	21
318	Neutralizing Antibody Response During Human Immunodeficiency Virus Type 1 Infection: Type and Group Specificity and Viral Escape. <i>Journal of General Virology</i> , 1993, 74, 855-863.	1.3	80
319	Transmission of zidovudine-resistant HIV-1. <i>Aids</i> , 1993, 7, 1684-1685.	1.0	27
320	Relationship between cell-free viraemia, antigenaemia and antibody levels in HIV-1-infected Ethiopian patients. <i>Aids</i> , 1992, 6, 651-658.	1.0	15
321	Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds. <i>Antiviral Research</i> , 1992, 19, 353-359.	1.9	1
322	Intrauterine and intrapartum transmission of HIV. <i>Lancet, The</i> , 1992, 339, 245-246.	6.3	25
323	HIV in pregnant women and their offspring: evidence for late transmission. <i>Lancet, The</i> , 1991, 338, 203-207.	6.3	222
324	Combined Treatment of Symptomatic Human Immunodeficiency Virus Type 1 Infection with Native Interferon- $\alpha$ and Zidovudine. <i>Journal of Infectious Diseases</i> , 1991, 163, 710-715.	1.9	38

#	ARTICLE	IF	CITATIONS
325	Detection of HIV-1 DNA and Infectious Virus in Cerebrospinal Fluid. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 369-373.	0.5	29
326	Interferon-Alpha and Tumor Necrosis Factor-Alpha in Serum of Patients in Various Stages of HIV-1 Infection. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 375-380.	0.5	201
327	Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection. <i>Infection</i> , 1990, 18, 347-351.	2.3	23
328	Detection of human immunodeficiency virus-1 by polymerase chain reaction and virus cultivation. <i>Journal of Medical Virology</i> , 1990, 31, 234-240.	2.5	29
329	Quantitative Detection of Brain Aberrations in Human Immunodeficiency Virus Type I-Infected Individuals by Magnetic Resonance Imaging. <i>Journal of Infectious Diseases</i> , 1990, 162, 1245-1251.	1.9	36
330	Treatment of HIV-1 Infected Patients with Peptide T. <i>Antiviral Chemistry and Chemotherapy</i> , 1990, 1, 349-354.	0.3	0
331	New subtype of HIV-1 in Ethiopia. <i>Lancet, The</i> , 1990, 336, 942-942.	6.3	17
332	Fine analysis of intrathecally synthesized anti-HIV IgG1-4 by peptide mapping. <i>Journal of the Neurological Sciences</i> , 1990, 100, 31-36.	0.3	5
333	Detection of Cell-Free Human Immunodeficiency Virus in Cerebrospinal Fluid by Using Immune Scanning Electron Microscopy. <i>Journal of Infectious Diseases</i> , 1989, 159, 1037-1041.	1.9	15
334	Non-specific reactivity in HIV antigen assay of sera from organ transplant recipients. <i>Infection</i> , 1989, 17, 168-169.	2.3	0
335	Relationship between the occurrence of virus in plasma and cerebrospinal fluid of hiv-1 infected individuals. <i>Journal of Medical Virology</i> , 1989, 27, 258-263.	2.5	10
336	IgG subclass reactivity against human immunodeficiency virus (HIV) and cytomegalovirus in cerebrospinal fluid and serum from HIV-infected patients. <i>Journal of Medical Virology</i> , 1988, 25, 17-26.	2.5	24
337	Efficient isolation of HIV from plasma during different stages of HIV infection. <i>Journal of Medical Virology</i> , 1988, 26, 23-32.	2.5	103
338	IgG subclasses of antibodies reacting with HIV and myelin basic protein in CSF from HIV infected patients. <i>Journal of Neuroimmunology</i> , 1988, 17, 258-259.	1.1	0
339	DECLINING LEVELS OF HIV P24 ANTIGEN IN SERUM DURING TREATMENT WITH FOSCARNET. <i>Lancet, The</i> , 1988, 331, 1052.	6.3	27
340	Isolation Frequency of Human Immunodeficiency Virus from Cerebrospinal Fluid and Blood of Patients with Varying Severity of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1988, 4, 351-358.	0.5	65
341	Increased Production of Malondialdehyde in Patients with HIV Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 287-290.	1.5	121
342	Detection of immunoglobulin M antibody in primary human immunodeficiency virus infection. <i>Aids</i> , 1988, 2, 11-16.	1.0	44

#	ARTICLE	IF	CITATIONS
343	Antigen detection in primary HIV infection. BMJ: British Medical Journal, 1988, 296, 238-240.	2.4	117
344	Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. Journal of Medical Virology, 1987, 23, 67-73.	2.5	115
345	Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. Journal of Virology, 1987, 61, 2017-2023.	1.5	164
346	Nitroblue Tetrazolium (NBT) Reduction by Neutrophilic Granulocytes in Patients with HTLV-III Infection. Scandinavian Journal of Infectious Diseases, 1986, 18, 101-103.	1.5	26